Broccoli sprouts after H. pylori eradication beneficial in type 2 diabetes
Broccoli sprouts powder had favorable effects on patients with type 2 diabetes when given as an alternative or complementary treatment after Helicobacter pylori eradication, according to research published in the Journal of Diabetes & Metabolic Disorders.
A regimen of broccoli sprouts powder reduced H. pylori and improved cardiovascular markers compared with a standard triple therapy of omeprazole, clarithromycin and amoxicillin.
Parvin Mirmiran, PhD, of Shahid Beheshti University of Medical Sciences in Tehran, Iran, and colleagues evaluated 77 patients who had type 2 diabetes and positive H. pylori stool antigen tests (HpSAg) randomly assigned to three treatment cohorts.
The standard triple therapy group (n=28) received omeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1,000 mg twice a day for 14 days, the broccoli sprouts powder group (n=25) received 6 g of powder each day for 28 days, and the remaining (n=24) received both regimens.
At 4 weeks, the researchers assessed H. pylori eradication rates through HpSAg. They also compared anthropometric measures, blood pressure, serum lipids and lipoproteins and serum high-sensitive C-reactive protein (hsCRP) against baseline data.
H. pylori eradication rates were 89.3% in the standard triple therapy group, 56% in the broccoli sprouts powder group and 91.7% in the combination group. After treatment, both systolic and diastolic BP showed significant decreases in the combination group (P<.05).
Serum triglycerides and ratio of triglycerides to HDL cholesterol increased with standard triple therapy (P<.05). Serum hsCRP levels were significantly reduced with broccoli sprouts powder (3 ± 2.5 at baseline vs. 2.3 ± 2.1 after treatment; P<.05).
“Standard triple therapy could increase serum triglycerides and triglycerides to HDL cholesterol ratio, as main cardiovascular risk factors, following H. pylori eradication in patients with type 2 diabetes,” the researchers wrote, “while broccoli sprouts powder, in addition to considerable effect on H. pylori eradication and related inflammation, could reduce the unfavorable effects of [standard triple therapy].”
Disclosure: This study was funded by the Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.